未经证实:血液中维生素D水平与心血管疾病风险之间的关系尚有争议。据我们所知,这是对超过100,000名患者数据的首次比较荟萃分析,旨在检查低维生素D水平与不良心血管事件的相关性。
UNASSIGNED:在线数据库,包括PubMed、询问Embase和CochraneCentral,以比较维生素D(HVD)和对照组的心血管结局。评估的结果包括主要不良心血管事件(MACE)的差异,死亡率,心肌梗塞,和心力衰竭。使用随机效应模型计算未调整的比值比(OR),其置信区间(CI)为95%,P小于0.05为统计学意义。
UNASSIGNED:本分析共纳入8项研究,包括426,039例患者。HVD组MACE发生率较高(OR1.92,95%CI1.24至2.98,p=0.003),而HVD与全因死亡率无显著关联(OR1.77,95%CI0.75-4.17,p=0.19),心肌梗死风险(OR0.69,95%CI0.39至1.24,p=0.22),和心力衰竭(OR1.20,95%CI0.34至4.25,p=0.78)。
未经评估:这项荟萃分析表明,维生素D的血液水平低与MACE有关,但是全因死亡率没有这种差异,观察到心肌梗死或心力衰竭。在选定的人群中适当补充维生素D可能具有心脏保护作用,因此需要进行广泛的试验。
UNASSIGNED: The relation between blood vitamin D levels and the risk of cardiovascular outcomes is debatable. To our knowledge this is the first comparative meta-analysis of more than 100,000 patients\' data with the aim to inspect the relevance of low vitamin D levels with adverse cardiovascular events.
UNASSIGNED: Online databases including PubMed, Embase and Cochrane Central were queried to compare the cardiovascular outcomes among hypovitaminosis D (HVD) and control group. The outcomes assessed included differences in major adverse cardiovascular events (MACE), mortality, myocardial infarction, and heart failure. Unadjusted odds ratios (OR) were calculated using a random-effect model with a 95% confidence interval (CI) and P less than 0.05 as a statistical significance.
UNASSIGNED: A total of 8 studies including 426,039 patients were included in this analysis. HVD group was associated with a higher incidence of MACE (OR 1.92, 95% CI 1.24 to 2.98, p = 0.003), while there was no significant association of HVD and all-cause mortality (OR 1.77, 95% CI 0.75 to 4.17, p = 0.19), risk of myocardial infarction (OR 0.69, 95% CI 0.39 to 1.24, p = 0.22), and heart failure (OR 1.20, 95% CI 0.34 to 4.25, p = 0.78).
UNASSIGNED: This meta-analysis suggested that low blood levels of vitamin D are associated with MACE, but no such difference in all-cause mortality, myocardial infarction or heart failure was observed. Appropriate supplementation of vitamin D in selected populations might be cardioprotective in nature and warrants extensive trials.